EORTC-1333-GUCG/PEACE III Trial Statement
28 Jun 2024
EORTC is pleased to announce that the phase III EORTC-1333-GUCG/PEACE III trial database is locked. It reached data maturity for its primary endpoint (radiological progression free survival) and analysis has started. The findings will be presented at an upcoming medical meeting and discussed with regulatory authorities.
The phase III EORTC-1333-GUCG/PEACE III trial is a randomised multicentre phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.
This trial is supported by an investigator driven clinical trial agreement from Bayer HealthCare Pharmaceuticals and Astellas Pharma Europe.
ENDS
Related News
New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
17 Sep 2024
Late Breaking Results from the EORTC 1333/PEACE III phase III trial
16 Sep 2024
EORTC-1333-GUCG/PEACE III trial endpoint reached
12 Jul 2024
Completion of Patient Recruitment for International TIGER Study
19 Dec 2022
EORTC Completes Patient Recruitment to Study of Treatment for Rare Cancer High-Grade Uterine Sarcoma
18 Oct 2021
Combined hormone/radiotherapy treatment improves event-free and disease-free survival in patients with localised intermediate risk prostate cancer; long-term results from EORTC Trial 22991
30 Jul 2021
Revisiting classification in testicular cancer: what has changed?
17 May 2021
Genito-urinary cancer research looks to the future
2 Dec 2020
Prostate cancer patient webinar underlines the importance of measuring the Quality of Life of caregivers
12 Nov 2020
Preliminary results confirm that the addition of bone-protecting agents to Radium-233 (Ra-233) treatment can limit fractures in metastatic castration resistant prostate cancer patients
31 May 2019
